Blog

CRI: “Immunotherapy prior to surgery could well become a game-changer” – Mark Saunders

Photo of Mark Saunders from oncology-forum.co.uk

Jun 14, 2024, 09:12

CRI: “Immunotherapy prior to surgery could well become a game-changer” – Mark Saunders

Cancer Research Institute (CRI) shared on LinkedIn: .

“According to clinical trial results presented at ASCO24, giving the immunotherapy drug pembrolizumab before surgery instead of chemotherapy resulted in a significant increase in patients with stage two or stage three MMR deficient/MSI-High bowel cancer being declared cancer-free following surgery.

‘Immunotherapy prior to surgery could well become a ‘game-changer’ for these patients,’ describes Dr. Mark Saunders, a Consultant Clinical Oncologist at The Christie NHS Foundation Trust.

Read more about these findings from UCL, University College London Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, University Hospital Southampton NHS FT, and University of Glasgow investigators.”

Source: Cancer Research Institute (CRI)/LinkedIn

ASCO ASCO24 bowel cancer cancer immunotherapy Leeds Teaching Hospitals NHS Trust Mark Saunders MMR deficient MSI-High OncoDaily Oncology pembrolizumab The Christie NHS Foundation Trust UCL University College London Hospitals NHS Foundation Trust University Hospital Southampton NHS FT University of Glasgow

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage